Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection

References

• CookeDTNguyenDVYangYChenSLYuCCalhounRFSurvival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomyAnn Thorac Surg201090394394820732522
   PubMed Web of Science ®Google Scholar
• GawrychowskiJBrulinskiKMalinowskiEPaplaBPrognosis and survival after radical resection of primary adenosquamous lung carcinomaEur J Cardiothorac Surg200527468669215784375
   PubMed Web of Science ®Google Scholar
• NakagawaKYasumituTFukuharaKShionoHKikuiMPoor prognosis after lung resection for patients with adenosquamous carcinoma of the lungAnn Thorac Surg20037561740174412822609
   PubMed Web of Science ®Google Scholar
• TravisWDWHO Classification of Tumours of the Lung, Pleura, Thymus and HeartInternational Agency for Research on Cancer2015
   Google Scholar
• ShimizuJOdaMHayashiYNonomuraAWatanabeYA clinicopathologic study of resected cases of adenosquamous carcinoma of the lungChest199610949899948635382
   PubMed Web of Science ®Google Scholar
• FilossoPLRuffiniEAsioliSAdenosquamous lung carcinomas: a histologic subtype with poor prognosisLung Cancer2011741252921371773
   PubMed Web of Science ®Google Scholar
• JiaXLChenGEGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lungLung Cancer201174339640021592614
   PubMed Web of Science ®Google Scholar
• KangSMKangHJShinJHIdentical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lungCancer2007109358158717186532
   PubMed Web of Science ®Google Scholar
• IwanagaKSueoka-AraganeNNakamuraTMoriDKimuraSThe long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinibInt Med2012511927712774
   PubMedGoogle Scholar
• SongZLinBShaoLZhangYTherapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinomaJ Chin Med Assoc201376948148523769878
   PubMed Web of Science ®Google Scholar
• ShukuyaTTakahashiTKairaREfficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reportsCancer Sci201110251032103721272159
   PubMedGoogle Scholar
• GoldstrawPCrowleyJChanskyKThe IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumoursJ Thorac Oncol20072870671417762336
   PubMed Web of Science ®Google Scholar
• TochigiNDacicSNikiforovaMCieplyKMYousemSAAdenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient populationAm J Clin Pathol2011135578378921502435
   PubMed Web of Science ®Google Scholar
• WangRPanYLiCAnalysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomasJ Thorac Oncol20149676076824481316
   PubMed Web of Science ®Google Scholar
• SasakiHEndoKYukiueHKobayashiYYanoMFujiiYMutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lungLung Cancer200755112913017156891
   PubMedGoogle Scholar
• TaoDHanXZhangNGenetic alteration profiling of patients with resected squamous cell lung carcinomasOncotarget Epub2016429
   Google Scholar
• DeardenSStevensJWuYLBlowersDMutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)Ann Oncol20132492371237623723294
   PubMed Web of Science ®Google Scholar
• ToyookaSYatabeYTokumoMMutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lungInt J Cancer200611861588159016187277
   PubMed Web of Science ®Google Scholar
• ShiXWuHLuJDuanHLiuXLiangZScreening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methodsSci Rep201662229726923333
   PubMedGoogle Scholar
• CiuleanuTStelmakhLCicenasSEfficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 studyLancet Oncol201213330030822277837
   PubMed Web of Science ®Google Scholar
• MaruyamaRNishiwakiYTamuraTPhase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancerJ Clin Oncol200826264244425218779611
   PubMed Web of Science ®Google Scholar
• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGFinal overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Ann Oncol20152691877188326141208
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• SoriaJCFelipECoboMAfatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialLancet Oncol201516889790726156651
   PubMed Web of Science ®Google Scholar
• VassellaELangschSDettmerMSMolecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?Oncotarget2015627239052391626068980
   PubMed Web of Science ®Google Scholar
• ShiozawaTIshiiGGotoKClinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lungPathol Int2013632778423464964
   PubMed Web of Science ®Google Scholar
• BurkartJShiloKZhaoWOzkanEAjamAOttersonGAMetastatic squamous cell carcinoma component from an adenosquamous carcinoma of the lung with identical epidermal growth factor receptor mutationsCase Rep Pulmonol20152015
   PubMedGoogle Scholar
• ChenJGaoYDCaoYYangJLuoGWSurgical specimen histology revealed inadequacy of conventional transbronchial needle aspiration sample in the diagnosis of adenosquamous lung carcinomaJ Thorac Dis20157468068625973234
   PubMed Web of Science ®Google Scholar